{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T17:52:04.729459+00:00","company":{"ticker":"VKTX","cik":1607678,"company_name":"Viking Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"e3f086251661791dbf93734bc5180bae8c57ab5b","cik":1607678,"ticker":"VKTX","company_name":"Viking Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":null},"claim":"Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On April 29, 2026, we issued a press release reporting our financial results for the first quarter ended March 31, 2026 and providing a corporate update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-191487","anchor_url":"https://secwatch.observer/filing/0001193125-26-191487#claim-e3f086251661791dbf93734bc5180bae8c57ab5b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/0001193125-26-191487-index.htm"},{"fact_type":"earnings_release","fact_key":"50a66246f8bee4dbead5f615d766d5ce294d4fe0","cik":1607678,"ticker":"VKTX","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-04-24","result_type":"reported_results","revenue_text":null},"claim":"Viking Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On April 24, 2024, we issued a press release reporting our financial results for the first quarter ended March 31, 2024 and providing a corporate update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-047567","anchor_url":"https://secwatch.observer/filing/0000950170-24-047567#claim-50a66246f8bee4dbead5f615d766d5ce294d4fe0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/0000950170-24-047567-index.htm"}]}